Healthcare investors are weighing two very different business profiles: Amgen, a large, cash-generative pharmaceutical company with broad commercial reach, and Axsome Therapeutics, a smaller biotech focused on central nervous system therapies and still ramping toward long-term profitability. The comparison centers on fundamentals—scale and cash flow for Amgen versus rapid revenue growth but persistent losses for Axsome—alongside contrasting risk exposures.
Key takeaways
- Amgen’s reported fiscal 2025 free cash flow was nearly $8.1 billion, reflecting strong cash generation and a net margin of 21%.
- Axsome Therapeutics grew fiscal 2025 revenue by about 65.5%, but remained unprofitable with a negative net margin of roughly 28.7%.
- Valuation metrics point to a gap between the companies, with Amgen trading at lower forward price-to-earnings and price-to-sales multiples than Axsome.
- The main implication for investors is a trade-off between stability and growth: Amgen’s mature model versus Axsome’s higher-risk, higher-trajectory execution.
What Amgen offers investors
Amgen is a diversified biopharmaceutical company operating across multiple therapeutic areas, including inflammation, rare disease, and oncology. The company’s product portfolio is distributed across roughly 100 countries, supported by large-scale commercialization.
Data for fiscal 2025 show revenue of nearly $36.7 billion, up approximately 9.9% year over year. Net income totaled roughly $7.7 billion, lifting profitability as reflected in a net margin of 21%. On the cash-flow front, Amgen generated free cash flow of nearly $8.1 billion during fiscal 2025.
Balance sheet metrics described for the period ended in December 2025 show a debt-to-equity ratio of 6.3 and a current ratio of about 1.1, indicating that while leverage is meaningful, liquidity is relatively tight. In addition, the company’s revenue concentration is notable: McKesson, Cencora, and Cardinal Health accounted for 77% of fiscal 2025 revenue, a factor that can introduce dependency risk even among established distribution partners.
What drives Axsome Therapeutics’ story
Axsome Therapeutics focuses on treatments for central nervous system conditions, including migraine and major depressive disorder. The company’s go-to-market strategy relies on commercialization in the United States, with partnerships used to broaden global reach, including research collaborations with Pfizer and AstraZeneca.
For fiscal 2025, Axsome reported revenue increase of about $638.5 million, which the article characterizes as 65.5% year-over-year growth. Despite this top-line momentum, Axsome continued to invest in its pipeline and reported a net loss of nearly $183.2 million. As a result, the company posted a net margin of approximately negative 28.7%, improving from the negative 74.5% net margin reported for 2024.
Financial metrics as of December 2025 show a debt-to-equity ratio of 2.7 and a current ratio around 1.6, suggesting current assets such as cash and receivables provided more coverage for short-term liabilities than Amgen’s snapshot. Axsome’s free cash flow remained negative, at about $93.9 million for the year, consistent with the cash burn typical of biotechs scaling commercial operations while funding pipeline development.
Risk comparison: pricing, concentration, and pipeline dependency
The risk profiles of the two companies differ sharply. For Amgen, the article points to pricing pressure from government and commercial payers, including Medicare price setting for key products such as ENBREL and Otezla. It also flags ongoing patent litigation and manufacturing concentration in Puerto Rico, a region historically susceptible to natural disasters. Separately, the piece notes cybersecurity concerns tied to prior incidents involving third-party vendors and data exfiltration.
Axsome’s risk framework is more pipeline and balance-sheet dependent. The article describes a relatively small product portfolio and an accumulated deficit of nearly $1.3 billion as of end-2025. It also highlights that much of Axsome’s intellectual property is licensed from an entity owned by the company’s CEO and chairman, creating potential conflict-of-interest and dependency considerations. In addition, like other drug developers, Axsome faces generic competition risk and ongoing funding needs to support clinical trials.
How valuation may influence investor choices
According to the valuation comparison included in the article, Amgen trades at substantially lower multiples than Axsome using forward P/E and price-to-sales measures. The piece cites forward P/E of 19.1 for Amgen versus 44.5 for Axsome, and price-to-sales of 6.5 for Amgen versus 16.7 for Axsome. It also notes that these valuation metrics were sourced from Financial Modeling Prep and may differ from other data providers.
For investors, the spread in valuation is consistent with the companies’ fundamentals as described: Amgen’s maturity, dividend-linked shareholder appeal, and cash generation tend to compress required returns. By contrast, Axsome’s higher growth rate and earlier-stage profitability trajectory can justify higher multiples, but also increases sensitivity to execution, commercial durability, and future financing needs.
What to watch next
Near-term, the key questions for Amgen are whether it can sustain cash generation amid payer pricing scrutiny and manage operational and legal risks without margin volatility. For Axsome, investors will likely focus on continued revenue momentum alongside progress toward improved profitability, as well as clarity around pipeline funding and long-term commercial traction. Both companies’ next catalysts typically include updates on financial results, guidance, and any material pipeline or regulatory milestones that could shift expectations for growth and margins.
